Investing.com - Sophia Genetics (NASDAQ: SOPH) reported third quarter EPS of $-0.280, $0.06 worse than the analyst estimate of $-0.220. Revenue for the quarter came in at $15.9M versus the consensus estimate of $15.86M.
Guidance
Sophia Genetics sees FY 2024 revenue of $65.000M-$67.000M versus the analyst consensus of $65.820M.
Sophia Genetics's stock price closed at $3.75. It is up 11.770% in the last 3 months and down -2.850% in the last 12 months.
Sophia Genetics saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Sophia Genetics's stock price’s past reactions to earnings here.
According to InvestingPro, Sophia Genetics's Financial Health score is "good performance".
Check out Sophia Genetics's recent earnings performance, and Sophia Genetics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar